Turn Therapeutics opened lower at $10.54, compared with its previous close of $10.57. In the last trading session, the stock traded between $9.99 and $10.50. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Turn Therapeutics is now worth
$ 144.64
Giving a profit of
$ 44.64 (44.64%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
66.67%
Hold
33.33%
Sell
0%
Markets Today
Today's Change
$-0.45 (-4.21%)
Day High
$10.50
Day Low
$9.99
Day Open
$10.54
Prev Close
$10.57
Volume
91,654
1W Return
3.11%
1M Return
-9.03%
3M Return
-1.98%
6M Return
160.95%
1Y Return
160.95%
Fundamentals
Market Cap ($ Mn)
310
PE Ratio
-
PB Ratio
425.65
PEG Ratio
-
ROE
-188.22%
ROCE
-101.07%
EPS (TTM)
-
Investment Returns
1 Week
3.11%
1 Month
-9.03%
3 Months
-1.98%
6 Months
160.95%
9 Months
180.47%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
22Oct
Turn Therapeutics to host BTIG fireside chat on Oct 28
Turn Therapeutics to host virtual fireside chat on October 28, 2026. Event focuses on GX-03 strategy for atopic dermatitis patient access. Speakers include CEO Bradley Burnam and Dr. Stephen M. Hahn. Session hosted by U.S. Bancorp | BTIG for institutional clients only.
22 days ago
20Aug
Turn Therapeutics publishes peer-reviewed data for GX-03
Turn Therapeutics released peer-reviewed findings for GX-03 from an in-vivo study. The candidate reduced IL-36 by ~50%, IL-31 by ~68%, and IL-4 by 16.7%. The data underscores strong efficacy against itch and early inflammation drivers.
Turn Therapeutics reported a Q2 EPS of $(0.20), missing estimates of $(0.02). The company logged a net loss of $5.8 million, driven by a $3.3 million non-cash loss on derivatives. Operational expenses rose to $1.6 million, with cash reserves at $10.3 million providing runway into Q3 2027.
3mo ago
8Jul
Turn expands GX-03 Phase 2 to full atopic dermatitis severity
Turn Therapeutics announced the expansion of its Phase 2 GX-03 trial to include the full spectrum of atopic dermatitis severity after an interim analysis showed efficacy in mild-to-moderate patients. The final Stage 2 design will enroll 120-135 patients and utilize the Hochberg multiple testing procedure. The company expects to complete enrollment in Q4 2026 and is funded through Q3 2027.
